Analyst Price Target is GBX 6,303.50
▼ -39.99% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is GBX 6,303.50, with a high forecast of £140 and a low forecast of GBX 74. The average price target represents a -39.99% upside from the last price of £105.04.
Current Consensus is
Moderate Buy
The current consensus among 6 contributing investment analysts is to moderate buy stock in AstraZeneca. This rating has held steady since April 2024, when it changed from a Hold consensus rating.
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Read More